Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Renal Biomarkers Market: By Biomarker Type, By Diagnostic Technique, By End User, and Geography.
Renal Biomarkers Market: By Biomarker Type, By Diagnostic Technique, By End User, and Geography.
Renal Biomarkers Market size was valued US$ 1042.1 billion by 2022 and expected to reach US$ 1454.08 billion by 2029, at a CAGR of 6.8% from 2023-2029. Renal diseases are one of the major cause of death in geriatric population. Renal biomarkers are measurable indicators used to screening, monitoring, and diagnosing the activity of renal diseases by determining their blood and urine levels. The biomarkers are administered into kidneys to determine the renal functions. The early diagnosis of renal diseases helps to take proper treatment before the irreversible damage of kidneys.
Study Period
2024-2030Base Year
2023CAGR
6.8%Largest Market
North AmericaFastest Growing Market
Asia Pacific
Increase in the prevalence of renal diseases due to rise in hypertension and diabetes in elderly patients is a major factor fuel the renal biomarkers market. Rise in geriatric population, increase in the R&D for the development of novel renal biomarkers, and using of renal biomarkers in preclinical and clinical trials to determine the safety of new drugs are anticipated to propel the market. However, stringent regulatory scenario, lack of specificity and sensitivity in current renal biomarkers, and lack of favorable reimbursement policies are anticipated to impede the growth of renal biomarkers market.
North America renal biomarkers market is expected to expand at significant CAGR due to its raising ageing population along with increased prevalence of renal disorders. The state-of-art healthcare infrastructure, and favorable reimbursement policies are expected to enhance the growth of renal biomarkers market. The existence of the manufacturers in large number, surge in R&D investments are expected to fuel the growth of market. The well established distribution channels further enhance the growth of the market. Europe market is anticipated to offer enormous opportunities for the market players plunged in market. Asia Pacific market is led by China, Japan, and India due to increasing geriatric population coupled with increased prevalence of renal disorders.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2022 |
US$ 1042.1 billion |
|
Market Size in 2029 |
US$ 1454.08 billion |
|
Market CAGR |
6.8% |
|
By Biomarker Type |
|
|
By Diagnostic Technique |
|
|
By End User |
|
|
By Region |
|
Download Free Sample Report
renal biomarkers market size valued US$ 1042.1 billion by 2022 and expected to reach US$ 1454.08 billion by 2029, at a CAGR of 6.8% during the forecast period 2023-2029
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
| 1.Executive Summary |
| 2.Global Renal Biomarkers Market Introduction |
| 2.1.Global Renal Biomarkers Market - Taxonomy |
| 2.2.Global Renal Biomarkers Market - Definitions |
| 2.2.1.Biomarker Type |
| 2.2.2.Diagnostic Technique |
| 2.2.3.End User |
| 2.2.4.Route of Administration |
| 2.2.5.Region |
| 3.Global Renal Biomarkers Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Renal Biomarkers Market Analysis, 2018-2022 and Forecast 2023-2029 |
| 4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Renal Biomarkers Market By Biomarker Type, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 5.1. Functional Biomarkers |
| 5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Up-Regulated Proteins |
| 5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Others |
| 5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 6.Global Renal Biomarkers Market By Diagnostic Technique, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 6.1. Particle enhanced turbidimetric immunoassay |
| 6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Chemiluminescent enzyme immunoassay |
| 6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Enzyme linked immunosorbent assay |
| 6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Colorimetric assay |
| 6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Liquid chromatography |
| 6.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 7.Global Renal Biomarkers Market By End User, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 7.1. Hospitals |
| 7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Outpatient Clinics |
| 7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Research Centers |
| 7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Diagnostic Labs |
| 7.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 8.Global Renal Biomarkers Market By Route of Administration, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 8.1. Injection |
| 8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Nasal Spray |
| 8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 9.Global Renal Biomarkers Market By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 9.1. North America |
| 9.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. Europe |
| 9.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 9.3. Asia Pacific (APAC) |
| 9.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.3.3. Market Opportunity Analysis |
| 9.4. Middle East and Africa (MEA) |
| 9.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.4.3. Market Opportunity Analysis |
| 9.5. Latin America |
| 9.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.5.3. Market Opportunity Analysis |
| 10.North America Renal Biomarkers Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 10.1. Biomarker Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Functional Biomarkers |
| 10.1.2.Up-Regulated Proteins |
| 10.1.3.Others |
| 10.2. Diagnostic Technique Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Particle enhanced turbidimetric immunoassay |
| 10.2.2.Chemiluminescent enzyme immunoassay |
| 10.2.3.Enzyme linked immunosorbent assay |
| 10.2.4.Colorimetric assay |
| 10.2.5.Liquid chromatography |
| 10.3. End User Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Hospitals |
| 10.3.2.Outpatient Clinics |
| 10.3.3.Research Centers |
| 10.3.4.Diagnostic Labs |
| 10.4. Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Injection |
| 10.4.2.Nasal Spray |
| 10.5. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.5.1.United States of America (USA) |
| 10.5.2.Canada |
| 11.Europe Renal Biomarkers Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 11.1. Biomarker Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Functional Biomarkers |
| 11.1.2.Up-Regulated Proteins |
| 11.1.3.Others |
| 11.2. Diagnostic Technique Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Particle enhanced turbidimetric immunoassay |
| 11.2.2.Chemiluminescent enzyme immunoassay |
| 11.2.3.Enzyme linked immunosorbent assay |
| 11.2.4.Colorimetric assay |
| 11.2.5.Liquid chromatography |
| 11.3. End User Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Hospitals |
| 11.3.2.Outpatient Clinics |
| 11.3.3.Research Centers |
| 11.3.4.Diagnostic Labs |
| 11.4. Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.Injection |
| 11.4.2.Nasal Spray |
| 11.5. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.5.1.Germany |
| 11.5.2.France |
| 11.5.3.Italy |
| 11.5.4.United Kingdom (UK) |
| 11.5.5.Spain |
| 11.5.6.Rest of EU |
| 12.Asia Pacific (APAC) Renal Biomarkers Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 12.1. Biomarker Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Functional Biomarkers |
| 12.1.2.Up-Regulated Proteins |
| 12.1.3.Others |
| 12.2. Diagnostic Technique Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Particle enhanced turbidimetric immunoassay |
| 12.2.2.Chemiluminescent enzyme immunoassay |
| 12.2.3.Enzyme linked immunosorbent assay |
| 12.2.4.Colorimetric assay |
| 12.2.5.Liquid chromatography |
| 12.3. End User Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Hospitals |
| 12.3.2.Outpatient Clinics |
| 12.3.3.Research Centers |
| 12.3.4.Diagnostic Labs |
| 12.4. Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.Injection |
| 12.4.2.Nasal Spray |
| 12.5. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.5.1.China |
| 12.5.2.India |
| 12.5.3.Australia and New Zealand (ANZ) |
| 12.5.4.Japan |
| 12.5.5.Rest of APAC |
| 13.Middle East and Africa (MEA) Renal Biomarkers Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 13.1. Biomarker Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Functional Biomarkers |
| 13.1.2.Up-Regulated Proteins |
| 13.1.3.Others |
| 13.2. Diagnostic Technique Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Particle enhanced turbidimetric immunoassay |
| 13.2.2.Chemiluminescent enzyme immunoassay |
| 13.2.3.Enzyme linked immunosorbent assay |
| 13.2.4.Colorimetric assay |
| 13.2.5.Liquid chromatography |
| 13.3. End User Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Hospitals |
| 13.3.2.Outpatient Clinics |
| 13.3.3.Research Centers |
| 13.3.4.Diagnostic Labs |
| 13.4. Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Injection |
| 13.4.2.Nasal Spray |
| 13.5. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.5.1.GCC Countries |
| 13.5.2.South Africa |
| 13.5.3.Rest of MEA |
| 14.Latin America Renal Biomarkers Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 14.1. Biomarker Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.1.1.Functional Biomarkers |
| 14.1.2.Up-Regulated Proteins |
| 14.1.3.Others |
| 14.2. Diagnostic Technique Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.2.1.Particle enhanced turbidimetric immunoassay |
| 14.2.2.Chemiluminescent enzyme immunoassay |
| 14.2.3.Enzyme linked immunosorbent assay |
| 14.2.4.Colorimetric assay |
| 14.2.5.Liquid chromatography |
| 14.3. End User Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.3.1.Hospitals |
| 14.3.2.Outpatient Clinics |
| 14.3.3.Research Centers |
| 14.3.4.Diagnostic Labs |
| 14.4. Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.4.1.Injection |
| 14.4.2.Nasal Spray |
| 14.5. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.5.1.Brazil |
| 14.5.2.Mexico |
| 14.5.3.Rest of LA |
| 15. Competition Landscape |
| 15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 15.2.1.Merck Millipore (U.S) |
| 15.2.2.Thermo Fisher Scientific Inc (U.S) |
| 15.2.3.Hoffmann-La Roche Ag (Switzerland) |
| 15.2.4.Abbott Molecular Inc (U.S) |
| 15.2.5.Beckman Coulter Inc (U.S) |
| 15.2.6.Astute Medical Inc (U.S) |
| 15.2.7.Randox Laboratories Ltd (Ireland) |
| 16. Research Methodology |
| 17. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.